Compare Gilead Sciences, Inc. (GILD) vs Primo Brands Corporation Class A Common Stock (PRMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Primo Brands Corporation Class A Common Stock — how do they compare? Gilead Sciences, Inc. trades at $155.08 (market cap $183.41B), while Primo Brands Corporation Class A Common Stock trades at $18.76 (market cap $6.84B). The key difference: Gilead Sciences, Inc. is far larger — about 26.8× Primo Brands Corporation Class A Common Stock's market cap, and Primo Brands Corporation Class A Common Stock pays the higher dividend (2.54%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 112 Days and Primo Brands Corporation Class A Common Stock for 0 Days on average.
| GILD | PRMB | |
|---|---|---|
Market Cap | $183.41B | $6.84B |
Volume | 5,557,651 | 2,864,594 |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $25.39 |
52-Week Low | $117.85 | $14.46 |
Typical Hold Time | 112 Days | 0 Days |
Enterprise Value | $206.48B | $12.17B |
Dividend Yield | 2.22% | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.92, down 1.67% on the day, with strong analyst support (67% buy ratings) and a $153.13 consensus price target. Recent quarterly earnings beat expectations despite a Q2 loss, while revenue growth remains steady. Technical indicators show a bullish trend with support at $147-149 and resistance at $152-154. The company continues expanding HIV treatment access through recent PAHO partnerships.
GILD presents a mixed fundamental picture with strong revenue growth but negative net margins. The stock offers upside to analyst targets but faces execution risks in oncology pipeline development and competitive pressures. Recent institutional selling and high debt levels warrant monitoring, though expanding HIV franchise provides stable cash flow foundation.
PRMB trades at $18.9, down 1.46% on the day, with a neutral technical signal and key support/resistance clustered around $19. The company reported Q2 2026 EPS of $0.37, beating expectations, and shows improving revenue and net income trends for 2026. Recent news highlights expansion with a new factory opening and strong premium water sales growth, supporting a positive analyst consensus.
The outlook is positive, driven by sales momentum and capacity expansion, but risks include thin net margins and high P/E ratio. With 80% of analysts rating it Buy and a consensus price target of $28.50, the stock offers significant upside potential if execution continues, though margin pressure remains a key watchpoint.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Primo Brands Corporation Class A Common Stock
Primo Brands Corporation is a branded beverage company that produces and distributes packaged and purified water, water dispensers, and filtration equipment across North America, under brands including Poland Spring, Pure Life, Arrowhead, and Primo Water.
Read more on PRMB →
